Reality star reveals ‘scary' hospital dash after suffering ‘episode' and mini stroke at 24
A REALITY TV star turned business owner has revealed a "really scary" health ordeal which left him "paralysed."
The Netflix series alum, 24, captured a snap from his hospital bed as he documented his hugely worrying "episode" for his followers.
6
Reality TV star Liam Brown has revealed a scary health incident which left him 'paralysed'
Credit: Instagram
6
The 24-year-old Snowflake Mountain alum posted a lengthy medical update to social media
Credit: Instagram
6
It came after the Coventry lad lost more than six stone with weight loss jabs
Credit: Pete Dadds
Snowflake Mountain contestant Liam Brown, who starred in the reality TV show back in 2022, is currently seeking treatment for a suspected mini stroke.
After uploading an image showing him in the medical ward, with his bed surrounded by blue curtains, he wrote: "Just a very sad update from me.
"Really scary situation but I am currently in hospital so for anyone trying to contact me sorry I haven't got back to you!"
Liam, who landed his "dream job" at InTheStyle following his reality TV stint before going on to found his company Rede Talent, continued: "Unfortunately, a few nights ago, I suffered a really scary turn in the middle of the night, essentially I was paralysed for 30 minutes and couldn't move or talk.
read more snowflake mountain
MOUNTAIN TO CLIMB Snowflake Mountain fans call out huge problem with Netflix reality show
"I came out of it and ignored it but my speech didn't fully return properly and then it happened again yesterday.
"I was taken into hospital and I'm being treated for a mini stroke also known as a Transient Ischemic Attack as I can't feel the right side of my face.
"But right now, they're not 100 per cent what caused this to happen, I'm undergoing so many tests, blood tests and scans to either try and find a blood clot or what caused this to happen."
He rounded off with the words: "Will keep everyone updated."
NEW LOOK
Liam's health shock came just weeks after we reported the TV star had lost a whopping 6.5stone through his use of fat jabs.
In April, he showcased before and after images of his impressive new look in a candid post on Instagram.
Netflix fans all have the same complaint about new show Snowflake Mountain where 'clueless kidults' get rude awakening
The TV star and businessman, who has spoke openly about his use of weight loss jabs, took to his Instagram grid for a post showcasing his new svelte look.
In words emblazoned on the snaps the Coventry lad wrote: "Probably needed a hug.
"Lost 6.5 stone instead."
Alongside the mirror selfies showing off his new slender figure he filled fans in on the finer details.
What are the other side effects of weight loss jabs?
Like any medication, weight loss jabs can have side effects.
Common side effects of injections such as Ozempic include:
Nausea: This is the most commonly reported side effect, especially when first starting the medication. It often decreases over time as your body adjusts.
Vomiting: Can occur, often in conjunction with nausea.
Diarrhea: Some people experience gastrointestinal upset.
Constipation: Some individuals may also experience constipation.
Stomach pain or discomfort: Some people may experience abdominal pain or discomfort.
Reduced appetite: This is often a desired effect for people using Ozempic for weight loss.
Indigestion: Can cause a feeling of bloating or discomfort after eating.
Serious side effects can also include:
Pancreatitis: In rare cases, Ozempic may increase the risk of inflammation of the pancreas, known as pancreatitis, which can cause severe stomach pain, nausea, and vomiting.
Kidney problems: There have been reports of kidney issues, including kidney failure, though this is uncommon.
Thyroid tumors: There's a potential increased risk of thyroid cancer, although this risk is based on animal studies. It is not confirmed in humans, but people with a history of thyroid cancer should avoid Ozempic.
Vision problems: Rapid changes in blood sugar levels may affect vision, and some people have reported blurry vision when taking Ozempic.
Hypoglycemia (low blood sugar): Especially if used with other medications like sulfonylureas or insulin.
He wrote: "I've been on Mounjaro 1 year this month so thought I'd jump on this trend!
"It's been a journey and not a very easy one at that, it's been hard at times and I've felt like giving it all up but I've stuck by my guns and kept pushing through.
"As I've now started lowering my doses and taking them every other week rather than every week, it gets more mentally challenging to fight away the thoughts every single day to slip back into old bad habits but I haven't come this far to just go 10 steps back!
"I have to look at my photos from then and now to motive me to carry on."
Mounjaro is an injectable prescription medicine that is used alongside diet and exercise to regulate blood sugar levels and promote weight loss.
Yet some users have reported horror stories of "almost dying" after using the drug.
TV CAREER
Snowflake Mountain saw 10 contestants put through their paces at a camp in order to try and kickstart them into standing on their own two feet.
The back-to-basics retreat was a rude awakening to just how pampered their lives had been so far.
There was no running water, no parents to wait on them - and worst of all, no Wi-Fi.
But by connecting to nature, they learned to graduate as fully-functioning adults, with a generous cash prize up for grabs.
Putting them through their paces were Joel and Matt - one a former Army Combat Engineer for almost 10 years and the other, a former member of the Navy Explosive Ordnance Disposal.
"Now, me and Matt, who survived off the land our whole lives, are gonna take these kids back to basics," Joel said.
"Why? Cause the wilderness forces you to toughen up! Are they gonna rise to the challenge or are they are gonna do what they do best? It's not gonna be easy!"
At the time, fans called out a glaring problem with the Netflix reality series.
As fans tuned in, many took to X with complaints about the conditions provided for the spoiled millennials.
Alongside an array of angry-faced emojis, one person penned: "The hilarious thing about Snowflake Mountain is that these kids are basically glamping. Terrible show."
6
Liam told how he was undergoing numerous tests after his suspected mini stroke
Credit: Instagram
6
He found fame on the reality series which saw 10 contestants sent to camp
Credit: Netflix
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
an hour ago
- Telegraph
NHS relaxes rules on weight-loss jabs for millions of diabetes patients
Millions more NHS patients could be offered Ozempic or Mounjaro in the biggest overhaul in diabetes treatment for a decade. The National Institute of Health and Care Excellence (Nice), the NHS medicines watchdog, has issued new draft guidance calling for the use of GLP-1 jabs, first developed for diabetes but now widely used for weight loss, to be ramped up significantly. It means the majority of people in Britain with type 2 diabetes – around five million in total – could be given the drugs to help prevent further illnesses. Experts hailed the proposed guidance as 'propelling treatment into the 21st century'. Prof Jonathan Benger, the deputy chief executive and chief medical officer at Nice, said the changes would mean 'more people will be offered medicines where it is right to do so'. He said: 'This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health.' He added that by recommending both classes of drug sooner, the NHS 'could help prevent heart attacks, strokes and other serious complications before they occur'. Drugs mimic hormones Under the draft guidance, doctors will be able to give the revolutionary drugs – GLP-1 receptor agonists – to diabetes patients who also have heart disease or are obese. They work by mimicking a hormone that regulates blood sugar and appetite. It has since also been revealed that they could help with a range of conditions such as cancer, heart disease and even dementia. Some 200,000 people are currently taking a GLP-1 injection on the NHS, three quarters of whom are using them for diabetes. The remainder are taking them for weight loss. It is thought as many as 1.3 million people in the UK are on the jabs privately. More than five million people in the UK are living with type 2 diabetes. It develops in adulthood and occurs when not enough of the hormone insulin is produced, leading to a rise in blood sugar levels. The new NHS guidance says the jabs should be considered in diabetes patients who have also been diagnosed with heart disease, heart failure, or have early onset type 2, which means they were diagnosed before age 40. People with both diabetes and obesity – a body mass index (BMI) over 35 – will also be able to get the jabs if they have not had success in bringing down their blood sugar levels within the first three months of using another drug. While there are no public figures on eligibility, millions of patients could fall into the relevant categories. It is common for people with diabetes to also suffer from heart issues and other related conditions, while up to 90 per cent are overweight or obese, with weight being the number one preventable cause of the condition. Diabetes UK estimates 168,000 people have early onset type 2, while the condition also causes about 250,000 heart attacks, strokes or cases of heart failure, each year – the leading cause of death in diabetes patients. Nice said the drugs were 'recommended as much for their cardiovascular benefits as for their glycaemic [blood sugar] benefits'. It estimates that 655,000 people with heart disease could benefit from the drugs, as well as 99,000 with early onset type 2. Nice said the initial rise in costs for the NHS would be offset in the longer term by reducing the need for other, sometimes more complex, treatment later on. It was revealed last week that the price of Mounjaro privately would be more than doubled from Sept 1 to a wholesale price of up to £300. The NHS bracing for an increase in demand and more people are expected to turn to competitor Wegovy. Some diabetes patients will already be eligible for, or taking, weight-loss jabs, on the NHS, but the draft guidance will mean more patients can access the drugs sooner without having to go to a specialist weight management service. To qualify for weight-loss drugs on the NHS, a person must currently have a BMI of over 40 and four related health conditions to receive Mounjaro, or attend a specialist weight management service, where waiting times can be up to a year or longer, with a BMI of over 35 and one related condition, to receive Wegovy. The draft guidance, which is out for consultation until October, also recommends making better use of another 'under-prescribed' class of drugs called SLGT-2 inhibitors. These daily pills include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. They reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. The new guidelines recommend patients who cannot tolerate metformin – the first choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. Drugs could protect heart and kidneys The watchdog said there was new evidence suggesting the drugs protect the heart and kidneys as well as controlling blood sugar, and could save almost 22,000 lives. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'
South Wales Guardian
2 hours ago
- South Wales Guardian
Type 2 diabetes patients set for major shake-up in care
The health service should move from a one-size-fits-all approach of starting everyone on the same medication, to more personalised care that aims to prevent complications like heart failure and heart attacks, according to new draft guidance from the National Institute for Health and Care Excellence (Nice). This includes making newer type 2 diabetes drugs, known as SGLT-2 inhibitors, a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, Nice said. It is estimated the change could save almost 22,000 lives once uptake reaches 90% of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. 'This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'
Leader Live
2 hours ago
- Leader Live
Type 2 diabetes patients set for major shake-up in care
The health service should move from a one-size-fits-all approach of starting everyone on the same medication, to more personalised care that aims to prevent complications like heart failure and heart attacks, according to new draft guidance from the National Institute for Health and Care Excellence (Nice). This includes making newer type 2 diabetes drugs, known as SGLT-2 inhibitors, a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, Nice said. It is estimated the change could save almost 22,000 lives once uptake reaches 90% of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. 'This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'
